Somite

Cellular Intelligence (formerly Somite.ai) successfully leverages its proprietary AI and DeltaStem platform to advance a lead cell therapy program (e.g., SMT-M01 for DMD) into early clinical trials, demonstrating strong efficacy and safety data. Strategic partnerships with large pharmaceutical companies accelerate development and validate the platform, leading to a significantly oversubscribed Series B round at a valuation exceeding $900M, driven by its unique data moat and technical milestones like scaling to 10M+ signal combinations.

Cellular Intelligence continues to make steady progress on its platform and preclinical programs, securing additional funding rounds at a moderate step-up in valuation. While the technology shows promise and achieves further technical milestones in data generation, the long development timelines and high capital requirements inherent in cell therapy result in a slower path to market, with valuation reaching approximately $350M-$400M as it approaches clinical milestones.

Cellular Intelligence faces significant challenges in translating its AI models into viable clinical candidates, or encounters unexpected regulatory hurdles and delays. Large pharmaceutical incumbents or well-funded AI biotech competitors launch similar initiatives, eroding Cellular Intelligence's competitive edge despite its proprietary technology. This leads to difficulty securing further funding or a down round, resulting in a valuation below its total capital raised (e.g., $47M), severely impacting common stock value given the $60M in liquidation preferences.